Acquisition by DKSH of NewBridge Pharmaceuticals

Niederer Kraft Frey advised DKSH on its entry into an agreement to acquire 100 per cent of NewBridge Pharmaceuticals for an enterprise value of USD 390 million. The transaction is subject to customary closing conditions.

DKSH is a leading market expansion services provider listed on SIX Swiss Exchange, active in Asia Pacific, Europe and North America across its Business Units Healthcare, Consumer Goods, Performance Materials and Technology.

NewBridge Pharmaceuticals is a Dubai-headquartered healthcare commercialization platform. Its acquisition represents a pivotal step in expanding DKSH Healthcare’s footprint beyond Asia Pacific and advances DKSH Healthcare’s strategic roadmap to become a leading multi-regional, end-to-end outsourcing platform.

The NKF team was led by Corporate/M&A partners Deirdre Ni Annrachain and Patrik Peyer and Financing partner Philip Spoerlé, working with associates Lorenzo Henseler and Leonard Reiter (both Financing).